Rebeccamycin analogues from indolo[2,3-c]carbazole

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Drug Discovery

Background:

• Glycosylated indolocarbazoles, inspired by the antibiotic rebeccamycin, are investigated for antitumor properties.
• Structure-activity relationship studies are essential for optimizing drug candidates.
• Natural indolocarbazoles feature an indolo[2,3-a]carbazole core, known for DNA intercalation and topoisomerase I inhibition.

Purpose of the Study:

• To synthesize and evaluate novel glycosylated indolocarbazole derivatives with a modified indolo[2,3-c]carbazole chromophore.
• To investigate the impact of structural modifications on DNA binding, topoisomerase I inhibition, and cytotoxicity.
• To determine the optimal structural features for potent antitumor activity.

Main Methods:

• Synthesis of new glycosylated indolocarbazole derivatives (compounds 7 and 8).
• Circular and electric linear dichroism measurements to assess DNA intercalation.
• DNA relaxation assays to evaluate effects on human DNA topoisomerase I.
• Cytotoxicity assays to determine drug efficacy.

Main Results:

• Compound 8 (N-methylated, mono-glycosylated) intercalates DNA, similar to natural analogues.
• Compound 7 (bis-glycosylated) showed a reduced capacity for stable DNA complex formation.
• Both compounds exhibited weak inhibition of human DNA topoisomerase I.
• Compound 8 demonstrated approximately 5-fold greater cytotoxicity than compound 7.
• The modified indolo[2,3-c]carbazole core was found to be detrimental to topoisomerase I-DNA complex stabilization.

Conclusions:

• The altered indolo[2,3-c]carbazole chromophore in derivatives 7 and 8 impairs DNA binding and topoisomerase I inhibition.
• Preserving the natural indolo[2,3-a]carbazole skeleton is critical for maintaining potent cytotoxic and topoisomerase I inhibitory activities.
• Structural modifications that hinder DNA intercalation and topoisomerase I inhibition reduce antitumor efficacy.